Cargando…

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF(V600E) Mutations

We describe a case of recurrent and metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) treated with anlotinib in this report. The patient was randomized to placebo initially, after disease progressed at C8 (C is the treatment cycle), the patient was referred to the ope...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yanjun, Cheng, Shaohao, Qian, Jun, Zhang, Min, Li, Tuanli, Zhang, Ying, Diao, Chang, Zhang, Ling, Cheng, Ruochuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024690/ https://www.ncbi.nlm.nih.gov/pubmed/33842329 http://dx.doi.org/10.3389/fonc.2021.626076

Ejemplares similares

Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAF(V600E) mutations: a case report
por: Su, Yan-Jun, et al.
Publicado: (2023)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

RAIRS Characterization of CO and O Coadsorption on Cu(111)
por: Zhang, Diyu, et al.
Publicado: (2022)

Surgical treatment of pediatric and adolescent papillary thyroid cancer: a retrospective study of 54 patients in a single center
por: Su, Yanjun, et al.
Publicado: (2022)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

The impact of the initial operation of PTC in children on recurrence: 9-year experience in a single center
por: Cheng, Shaohao, et al.
Publicado: (2022)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells
por: Jin, Hui, et al.
Publicado: (2013)

Methylidyne Adsorption on Pt(211) Probed by Reflection Absorption Infrared Spectroscopy (RAIRS)
por: Vejayan, Harmina, et al.
Publicado: (2022)

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
por: Shi, Liang, et al.
Publicado: (2022)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
por: Rusinek, Dagmara, et al.
Publicado: (2018)

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
por: Williams, Casey B, et al.
Publicado: (2015)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Hydroxyapatite Surfaces Functionalized with a Self-Assembling Peptide: XPS, RAIRS and NEXAFS Study
por: Secchi, Valeria, et al.
Publicado: (2020)

Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report
por: Liao, Lianggong, et al.
Publicado: (2020)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
por: Odogwu, Lauretta, et al.
Publicado: (2018)

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study
por: Fu, Hao, et al.
Publicado: (2019)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
por: Perrone, Fabiana, et al.
Publicado: (2022)

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation()()
por: Caruso, Maria, et al.
Publicado: (2014)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
por: Wu, Yongxing, et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
por: Fernandes, Gustavo S., et al.
Publicado: (2018)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
por: Wang, Wei, et al.
Publicado: (2021)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pf7dr1cg96jljcgpedda77m10o